Eli Lilly的糖尿病药物在降低血糖和减轻体重方面表现优于对手。 Eli Lilly's diabetes drug outperformed a rival in lowering blood sugar and aiding weight loss, according to a direct trial.

Eli Lilly的糖尿病药物显示,根据公司公告,在直接头对头的审判中,与对抗药物相比,血糖控制和体重减退的结果比较优越。 Eli Lilly's diabetes drug demonstrated superior blood sugar control and weight loss results compared to a rival medication in a direct head-to-head trial, according to company announcements. 调查结果表明,该药物可为管理2型糖尿病和肥胖症的病人提供更好的好处,使其在新陈代谢疾病治疗的日益增长的市场上成为强大的竞争对手。 The findings suggest the drug may offer improved benefits for patients managing type 2 diabetes and obesity, positioning it as a strong competitor in the growing market for metabolic disease treatments.